- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07950150
Pomegranate-Prebiotic Supplementation for Sarcopenic Obesity
The Efficacy of Pomegranate-Prebiotic Supplementation to Enhance Beneficial Phytochemicals in Older Adults With Sarcopenic Obesity
Sarcopenic obesity (SO) in older adults involves the co-occurrence of skeletal muscle decline and excessive body fat. This project investigates the gut-muscle axis, specifically how gut bacteria convert dietary polyphenols (such as ellagic acid found in pomegranates) into a muscle-protecting metabolite called Urolithin A (UA). This study is a randomized crossover pilot trial in 30 older adults with SO. It tests whether combining a pomegranate extract supplement with a prebiotic (Fructo-oligosaccharides, or FOS) increases the body's production of UA more effectively than pomegranate extract alone over a 7-day period.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Background and Rationale Sarcopenic obesity (SO) is a major public health challenge that significantly increases the risk of frailty, functional dependence, and metabolic comorbidities in aging populations. Current lifestyle and nutritional interventions often fail to address the underlying mitochondrial dysfunction and chronic low-grade inflammation central to the pathogenesis of SO. Recently, the gut-muscle axis has emerged as a therapeutic target. Urolithin A (UA) is a gut-derived microbial metabolite synthesized from dietary ellagitannins and ellagic acid (abundant in pomegranates) that activates mitophagy and improves mitochondrial health in skeletal muscle. However, UA synthesis is highly variable and depends on individual gut microbial composition, which is often compromised in older adults with obesity and sarcopenia (dysbiosis). Recent evidence suggests that prebiotics like Fructo-oligosaccharides (FOS) can promote the specific bacterial strains (Bifidobacterium and Enterococcus species) required for the two-step bioconversion of ellagic acid into UA.
This is a clinical pilot trial designed to test the feasibility and biological efficacy of a synergistic nutritional intervention. A total of 30 older adults diagnosed with SO will be enrolled in a randomized crossover trial. Each participant will undergo two 7-day intervention periods separated by a 14-day washout period.
Intervention A includes pomegranate extract alone (yielding 200 mg/day of ellagic acid). Intervention B includes pomegranate extract (yielding 200 mg/day of ellagic acid) combined with FOS prebiotic powder (5 g/day).
Because each participant serves as their own control, the crossover design eliminates the confounding effect of individual variability in baseline gut microbiome composition. The primary outcome is the within-participant difference in 24-hour urinary UA excretion (normalized to creatinine) between the combined intervention and the single-component intervention. Secondary outcomes include changes in fecal urolithin concentrations and shifts in gut microbiota composition assessed via 16S rRNA sequencing. Findings will inform the design of a fully powered randomized controlled trial testing this cost-effective synbiotic strategy for managing SO.
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Ka Hei Kenneth Lo, PhD
- Telefonnummer: 852-3400-8778
- E-post: kenneth.kh.lo@polyu.edu.hk
Studieorter
-
-
-
Hong Kong, Kina
- The Hong Kong Polytechnic University
-
Kontakt:
- Ka Hei Kenneth Lo, PhD
- Telefonnummer: 852-3400-8778
- E-post: kenneth.kh.lo@polyu.edu.hk
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- 65 years or older.
- Confirmed diagnosis of Sarcopenic Obesity (SO) according to 2022 ESPEN-EASO consensus and AWGS criteria:
- Obesity Component: BF% ≥25% (men) / ≥35% (women); OR BMI ≥23kg/m2; OR waist circumference >90cm (men) / >80cm (women).
- Sarcopenia Component: Low relative skeletal muscle mass combined with low handgrip strength (<28 kg men / <18kg women) and/or low physical performance (5-time chair stand ≥12s or gait speed <1.0m/s).
- Able and willing to provide informed consent.
- Willing and able to comply with all study procedures, dietary supplementation, and sample collections (24-hour urine and fecal samples).
Exclusion Criteria:
- Current regular intake of pomegranate, ellagitannin, or prebiotic supplements.
- Known hypersensitivity or allergy to pomegranate or fructo-oligosaccharides (FOS).
- History of renal diseases, renal replacement therapy, active cancer, severe cognitive impairment, or severe cardiac or hepatic dysfunction.
- Exposure to systemic antibiotics within 3 months prior to enrollment.
- Current participation in any other active interventional clinical trial.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Grundläggande vetenskap
- Tilldelning: Randomiserad
- Interventionsmodell: Crossover tilldelning
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Pomegranate Extract Alone (Active Control)
Participants will complete a 7-day intervention period receiving dietary supplementation with pomegranate extract alone. |
Two tablets daily of commercial pomegranate extract (Puritan's Pride), providing a total daily dose of 500 mg pomegranate fruit extract containing 200 mg ellagic acid (EA). Administered orally for 7 consecutive days. |
|
Experimentell: Pomegranate Extract + Fructo-oligosaccharides (FOS)
Participants will complete a 7-day intervention period receiving dietary supplementation with pomegranate extract in combination with FOS prebiotic powder. |
Two tablets daily of commercial pomegranate extract (Puritan's Pride), providing a total daily dose of 500 mg pomegranate fruit extract containing 200 mg ellagic acid (EA). Administered orally for 7 consecutive days. Two teaspoons (5 g/day) daily of Source Naturals FOS Powder. Provided as pre-measured daily sachets of bulk powder to be mixed with water, juice, or food and consumed orally for 7 consecutive days. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
24-Hour Urinary Urolithin A Excretion
Tidsram: Day 7 of Period 1 and Day 7 of Period 2 (at the end of each 7-day intervention period).
|
Within-participant difference in 24-hour total urinary urolithin A excretion normalized to urinary creatinine between the Pomegranate Extract + FOS intervention period and the Pomegranate Extract Alone intervention period. Measured via UHPLC-MS/MS. |
Day 7 of Period 1 and Day 7 of Period 2 (at the end of each 7-day intervention period).
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
24-Hour Total Urinary Urolithins Profile
Tidsram: Change from baseline (Day 0) to Day 7 within each 7-day intervention period.
|
Total excretion of urolithin metabolites and intermediates (including urolithin B and urolithin C) measured in 24-hour batch urine samples using UHPLC-MS/MS. |
Change from baseline (Day 0) to Day 7 within each 7-day intervention period.
|
|
Gut Microbiota Composition
Tidsram: Change from baseline (Day 0) to Day 7 within each 7-day intervention period.
|
Relative abundance and community structure of target gut bacteria (including Bifidobacterium species and urolithin-converting taxa) determined by 16S rRNA gene sequencing (V3-V4 hypervariable region) on an Illumina MiSeq platform. |
Change from baseline (Day 0) to Day 7 within each 7-day intervention period.
|
|
Fecal Urolithin Concentrations
Tidsram: Change from baseline (Day 0) to Day 7 within each 7-day intervention period.
|
Concentrations of urolithin A, urolithin B, and urolithin C in self-collected homogenized fecal samples, extracted and quantified via UHPLC-MS/MS. |
Change from baseline (Day 0) to Day 7 within each 7-day intervention period.
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Neurologiska manifestationer
- Muskuloskeletala sjukdomar
- Sjukdomar i nervsystemet
- Muskelsjukdomar
- Neuromuskulära manifestationer
- Patologiska processer
- Näringsstörningar
- Patologiska tillstånd, anatomiska
- Övernäring
- Kroppsvikt
- Övervikt
- Muskelatrofi
- Atrofi
- Patologiska tillstånd, tecken och symtom
- Närings- och metabola sjukdomar
- Tecken och symtom
- Fetma
- Dysbios
- Muskelsvaghet
- Sarkopeni
- Kosttillskott
- Mat
- Diet, mat och näring
- Fysiologiska fenomen
- Mat och dryck
- Dietkolhydrater
- Kolhydrater
- Polysackarider
- Dietfiber
- Polysackarider, bakterie
- Prebiotika
- fruktosackarid
- pomegranate fruit rind
Andra studie-ID-nummer
- HSEARS20260821008
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .